JP2022541341A - ステロイド二量体を含む物品と治療剤の送達におけるそれらの使用 - Google Patents

ステロイド二量体を含む物品と治療剤の送達におけるそれらの使用 Download PDF

Info

Publication number
JP2022541341A
JP2022541341A JP2022505341A JP2022505341A JP2022541341A JP 2022541341 A JP2022541341 A JP 2022541341A JP 2022505341 A JP2022505341 A JP 2022505341A JP 2022505341 A JP2022505341 A JP 2022505341A JP 2022541341 A JP2022541341 A JP 2022541341A
Authority
JP
Japan
Prior art keywords
article
linear
branched
formula
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022505341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541341A5 (https=
Inventor
パッラグ，イアン，チャールズ
ジョン ステイハム，マシュー，アレクサンダー
サンテール，ジェイ．，ポール
ナイマーク，ウェンディ，アリソン
デーリー，アダム，ブルース
Original Assignee
リップル セラピューティクス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リップル セラピューティクス コーポレーション filed Critical リップル セラピューティクス コーポレーション
Publication of JP2022541341A publication Critical patent/JP2022541341A/ja
Publication of JP2022541341A5 publication Critical patent/JP2022541341A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022505341A 2019-07-25 2020-07-24 ステロイド二量体を含む物品と治療剤の送達におけるそれらの使用 Pending JP2022541341A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962878477P 2019-07-25 2019-07-25
US62/878,477 2019-07-25
PCT/IB2020/000620 WO2021014217A1 (en) 2019-07-25 2020-07-24 Articles comprising steroid dimers and their use in the delivery of therapeutic agents

Publications (2)

Publication Number Publication Date
JP2022541341A true JP2022541341A (ja) 2022-09-22
JP2022541341A5 JP2022541341A5 (https=) 2023-08-01

Family

ID=74192465

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022505341A Pending JP2022541341A (ja) 2019-07-25 2020-07-24 ステロイド二量体を含む物品と治療剤の送達におけるそれらの使用

Country Status (5)

Country Link
US (1) US20220289787A1 (https=)
EP (1) EP4003362A4 (https=)
JP (1) JP2022541341A (https=)
CN (1) CN114728011A (https=)
WO (1) WO2021014217A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111971292B (zh) 2018-02-02 2024-12-13 波纹疗法公司 包含类固醇二聚体的玻璃制剂及其用途
WO2020154815A1 (en) 2019-02-01 2020-08-06 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
US12509469B2 (en) 2019-08-07 2025-12-30 Ripple Therapeutics Corporation Compositions and methods for the treatment of pain and dependence disorders
WO2021220061A2 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
WO2024013565A1 (en) * 2022-07-12 2024-01-18 Ripple Therapeutics Corporation Compositions and methods for improving vision
WO2025049690A1 (en) * 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04506508A (ja) * 1989-03-09 1992-11-12 エンドコン・インコーポレーテッド 部分融合ペプチドペレット

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010437A1 (en) * 1989-03-09 1990-09-20 Endocon, Inc. Partially fused peptide pellet
WO1995020567A1 (en) * 1994-01-28 1995-08-03 University Of Kentucky Research Foundation Codrugs as a method of controlled drug delivery
US9056048B2 (en) * 2001-08-16 2015-06-16 The Trustees Of The University Of Pennsylvania Synthesis and use of cationic steroids for anti-inflammatory drug therapy
US20030158598A1 (en) * 2001-09-17 2003-08-21 Control Delivery Systems, Inc. System for sustained-release delivery of anti-inflammatory agents from a coated medical device
ES2773179T3 (es) * 2013-03-15 2020-07-09 Ripple Therapeutics Corp Artículo médico recubierto para liberación de fármacos
AU2016354564B2 (en) * 2015-11-12 2021-04-29 Board Of Regents Of The University Of Nebraska Polyethylene glycol-conjugated glucocorticoid prodrugs and compositions and methods thereof
CN111971292B (zh) * 2018-02-02 2024-12-13 波纹疗法公司 包含类固醇二聚体的玻璃制剂及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04506508A (ja) * 1989-03-09 1992-11-12 エンドコン・インコーポレーテッド 部分融合ペプチドペレット

Also Published As

Publication number Publication date
US20220289787A1 (en) 2022-09-15
EP4003362A4 (en) 2023-11-15
WO2021014217A1 (en) 2021-01-28
CN114728011A (zh) 2022-07-08
EP4003362A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
JP2022541341A (ja) ステロイド二量体を含む物品と治療剤の送達におけるそれらの使用
US20230225975A1 (en) Dexamethasone prodrug compositions and uses thereof
JP6272454B2 (ja) ジエチレングリコールモノエチルエーテル又は他のアルキル誘導体を含む医薬活性成分の組成物
JP2022185059A (ja) 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物
WO2020227353A1 (en) Injectable sustained-release formulations for treatment of joint pain and inflammation
WO2013065028A1 (en) Fixed dose combination containing azithromycin and loteprednol for treatment of ocular infections
US20220288277A1 (en) Surface coatings and implantable devices comprising dimeric steroid prodrugs, and uses thereof
WO2012093117A1 (en) Methods and pharmaceutical compositions for the treatment of ocular inflammatory diseases
CA3114061A1 (en) Liquid polymer delivery system for extended administration of drugs
AU2009253956B2 (en) Composition comprising an antibiotic and a corticosteroid
AU2017260327A1 (en) Pharmaceutical Ophthalmic compositions and methods for fabricating thereof
WO2020051644A1 (en) Treatment of peripheral nervous tissue inflammation
JP2023524494A (ja) 眼障害を処置するためのヘテロ二量体組成物と方法
EP3265103B1 (en) Compositions comprising an aldosterone antagonist for use in treating dry eyes
JP2021506956A (ja) 状態を予防及び治療するための組成物及び方法
US20250057962A1 (en) Processable compositions and use for the same
AU2005234785A1 (en) Angiostatic agents for controlling choroidal neovascularisation after ocular surgery of trauma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220812

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230721

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250129